Do analysts rate ATRA or TXMD?

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential downside of 18.45%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atara Biotherapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BMEA or TXMD?

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 502.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate TXMD or KLRS?

Kalaris Therapeutics has a consensus price target of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts rate TXMD or CGTX?

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 184.90%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

TherapeuticsMD (TXMD) Competitors

$2.11 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

TXMD vs. ATRA, BMEA, BDTX, KLRS, and CGTX

Should you buy TherapeuticsMD stock or one of its competitors? MarketBeat compares TherapeuticsMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TherapeuticsMD include Atara Biotherapeutics (ATRA), Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Kalaris Therapeutics (KLRS), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.

How does TherapeuticsMD compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Atara Biotherapeutics has higher revenue and earnings than TherapeuticsMD. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17

TherapeuticsMD has a net margin of 5.34% compared to Atara Biotherapeutics' net margin of -40.91%. TherapeuticsMD's return on equity of 0.32% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
TherapeuticsMD	5.34%	0.32%	0.23%

In the previous week, Atara Biotherapeutics' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
TherapeuticsMD	Neutral

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential downside of 18.45%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atara Biotherapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Summary

Atara Biotherapeutics beats TherapeuticsMD on 7 of the 13 factors compared between the two stocks.

How does TherapeuticsMD compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 502.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TherapeuticsMD has a net margin of 5.34% compared to Biomea Fusion's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
TherapeuticsMD	5.34%	0.32%	0.23%

In the previous week, Biomea Fusion's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Biomea Fusion	Neutral
TherapeuticsMD	Neutral

Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17

Summary

TherapeuticsMD beats Biomea Fusion on 7 of the 12 factors compared between the two stocks.

How does TherapeuticsMD compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Black Diamond Therapeutics has higher revenue and earnings than TherapeuticsMD. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.65	$22.37M	-$0.77	N/A
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17

Black Diamond Therapeutics currently has a consensus target price of $9.83, suggesting a potential upside of 389.22%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for TherapeuticsMD. Black Diamond Therapeutics' average media sentiment score of 0.68 beat TherapeuticsMD's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
TherapeuticsMD	Neutral

TherapeuticsMD has a net margin of 5.34% compared to Black Diamond Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
TherapeuticsMD	5.34%	0.32%	0.23%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Black Diamond Therapeutics has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Summary

Black Diamond Therapeutics beats TherapeuticsMD on 11 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to Kalaris Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Kalaris Therapeutics has a consensus price target of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Kalaris Therapeutics	Neutral

TherapeuticsMD has a net margin of 5.34% compared to Kalaris Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

TherapeuticsMD has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TherapeuticsMD beats Kalaris Therapeutics on 7 of the 13 factors compared between the two stocks.

How does TherapeuticsMD compare to Cognition Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Cognition Therapeutics had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 equaled Cognition Therapeutics'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Cognition Therapeutics	Neutral

TherapeuticsMD has a net margin of 5.34% compared to Cognition Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 184.90%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

TherapeuticsMD has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cognition Therapeutics beats TherapeuticsMD on 7 of the 13 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.42M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	N/A	20.06	27.78	24.70
Price / Sales	8.08	360.34	540.55	99.42
Price / Cash	45.23	57.49	49.26	57.09
Price / Book	0.91	4.32	10.96	6.46
Net Income	-$570K	$64.45M	$3.57B	$337.01M
7 Day Performance	N/A	2.97%	2.12%	1.69%
1 Month Performance	6.03%	6.83%	5.25%	3.81%
1 Year Performance	88.39%	29.07%	33.29%	23.90%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	0.9851 of 5 stars	$2.11 flat	N/A	+88.4%	$24.42M	$3.02M	N/A	420
ATRA Atara Biotherapeutics	0.6981 of 5 stars	$11.48 +2.8%	$9.50 -17.2%	+45.4%	$100.64M	$120.77M	N/A	330
BMEA Biomea Fusion	1.9474 of 5 stars	$1.47 +5.8%	$8.50 +478.2%	-14.8%	$100.50M	N/A	N/A	50	Positive News Analyst Downgrade
BDTX Black Diamond Therapeutics	3.7416 of 5 stars	$1.85 +5.7%	$9.83 +431.5%	-22.1%	$100.28M	$70M	N/A	90	Positive News
KLRS Kalaris Therapeutics	3.5395 of 5 stars	$4.07 -3.6%	$15.60 +283.3%	+90.0%	$100.28M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. ATRA, BMEA, BDTX, KLRS, and CGTX

How does TherapeuticsMD compare to Atara Biotherapeutics?

Summary

How does TherapeuticsMD compare to Biomea Fusion?

Summary

How does TherapeuticsMD compare to Black Diamond Therapeutics?

Summary

How does TherapeuticsMD compare to Kalaris Therapeutics?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. ATRA, BMEA, BDTX, KLRS, and CGTX

How does TherapeuticsMD compare to Atara Biotherapeutics?

Which has better earnings & valuation, ATRA or TXMD?

Is ATRA or TXMD more profitable?

Does the media refer more to ATRA or TXMD?

Do analysts rate ATRA or TXMD?

Do institutionals & insiders have more ownership in ATRA or TXMD?

Which has more risk and volatility, ATRA or TXMD?

Summary

How does TherapeuticsMD compare to Biomea Fusion?

Do analysts recommend BMEA or TXMD?

Do insiders & institutionals have more ownership in BMEA or TXMD?

Is BMEA or TXMD more profitable?

Does the media refer more to BMEA or TXMD?

Which has more risk & volatility, BMEA or TXMD?

Which has preferable valuation & earnings, BMEA or TXMD?

Summary

How does TherapeuticsMD compare to Black Diamond Therapeutics?

Which has preferable valuation and earnings, BDTX or TXMD?

Do analysts prefer BDTX or TXMD?

Does the media refer more to BDTX or TXMD?

Is BDTX or TXMD more profitable?

Do institutionals & insiders hold more shares of BDTX or TXMD?

Which has more risk & volatility, BDTX or TXMD?

Summary

How does TherapeuticsMD compare to Kalaris Therapeutics?

Do analysts rate TXMD or KLRS?

Which has more risk and volatility, TXMD or KLRS?

Does the media prefer TXMD or KLRS?

Is TXMD or KLRS more profitable?

Which has preferable valuation and earnings, TXMD or KLRS?

Do institutionals and insiders have more ownership in TXMD or KLRS?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Does the media favor TXMD or CGTX?

Is TXMD or CGTX more profitable?

Do analysts rate TXMD or CGTX?

Which has better valuation and earnings, TXMD or CGTX?

Which has more risk & volatility, TXMD or CGTX?

Do institutionals & insiders believe in TXMD or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools